Local view for "http://purl.org/linkedpolitics/eu/plenary/2008-10-22-Speech-3-038"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2008-10-22"^^xsd:date2
dcterms:Is Part Of	lp_eu:Variations to the terms of marketing authorisations for medicinal products - Counterfeiting of medicinal products (debate)2
dcterms:Language	"el"^^xsd:language2
lpv:document identification number	"en.20081022.2.3-038"2
lpv:hasSubsequent	lp_eu:2008-10-22-Speech-3-0392
lpv:speaker	lp:Emmanouil Angelakas2
lpv:spokenAs	unknown; Nea Dimokratia (2007-10-01--2009-07-13)3 member; Delegation to the EU-Russia Parliamentary Cooperation Committee (2007-10-11--2009-07-13)3 member; EPP-ED (2007-10-01--2009-07-13)3 substitute; IMCO (2007-10-10--2009-07-13)3 member; REGI (2007-10-11--2009-07-13)3
lpv:translated text	"Mr President, I too should like to congratulate the rapporteur and to make two comments in reply to the Commissioner. Firstly, as far as the trade in counterfeit medicinal products is concerned, we were surprised to learn that some of them are being produced in two countries of the European Union and then marketed through a third European country, namely Switzerland. This is something you need to look into, Commissioner. My second comment concerns the industry which produces raw materials for medicinal products, which may have been flourishing 20 years ago, but which is now slowly dying. The reasons are, firstly, the high costs and, secondly, the protection of innovation, about which we are all agreed, but which has resulted in European companies being unable to manufacture raw materials for medicinal products which come under the rules protecting innovation. As a result, research centres have moved to China and India. There are certain policies which you can apply so that they return to the European Union."@en1
lpv:videoURI	<go to Events_and_structure europarl>2

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph